Autophagy: Molecular mechanisms and overview

Autophagy is an evolutionarily conserved lysosomal degradation pathway through which eukaryotic cells sequester and recycle cytoplasmic material, ranging from soluble proteins and lipid droplets to entire organelles and intracellular pathogens. It operates constitutively to maintain proteostasis and is dynamically upregulated in response to nutrient, energetic, and proteotoxic stress.

This page focuses on the types of autophagy, regulatory logic, selective autophagy, and disease relevance. For a step-by-step description of the core machinery — ULK1 and PI3KC3 complexes, ATG9/ATG2 lipid transfer, LC3 lipidation, and lysosomal fusion — see our companion page: The autophagy pathway: key stages and molecular machinery.

Biological context and physiological roles

Basal autophagy provides continuous quality control, clearing damaged organelles, misfolded proteins, and aggregates that would otherwise compromise cellular function. Under stress conditions such as nutrient deprivation, hypoxia, oxidative damage, or infection, autophagic flux rapidly increases to release amino acids, fatty acids, and nucleotides that sustain bioenergetics and biosynthesis until homeostasis is restored¹.

Beyond housekeeping, autophagy shapes differentiation, embryonic development, innate and adaptive immunity, and lifespan regulation. Its outputs feed directly into central metabolic pools, meaning that autophagic activity is tightly coupled to the nutrient- and energy-sensing networks that govern cell growth. This integration explains why autophagy dysregulation manifests across such a broad spectrum of pathology².

Types of autophagy in mammalian cells

Three mechanistically distinct routes deliver cargo to the lysosome. They differ in how cargo is captured, which machinery is required, and the physiological contexts in which they dominate.

Macroautophagy is by far the most extensively characterized route and is referred to simply as "autophagy" in the sections below. Its stepwise mechanism, from ULK1 activation to lysosomal fusion, is described in detail on the pathway page.

Regulation of autophagy

Autophagy is controlled by a signaling network that integrates nutrient availability, energy status, and cellular stress. The dominant regulators are mTORC1, AMPK, and the TFEBfamily of transcription factors, which together set both acute autophagic flux and longer-term degradative capacity³.

mTORC1

mTORC1 is the principal negative regulator. Under nutrient-replete conditions, mTORC1 inhibits the ULK1 complex to block autophagy initiation and retains TFEB in the cytosol to suppress transcription of autophagy and lysosomal genes. Nutrient withdrawal or mTORC1 inhibition rapidly releases this brake³.

AMPK

AMPK is the principal positive regulator. When cellular energy falls, AMPK activates the ULK1 complex directly and inhibits mTORC1 indirectly, coordinately switching autophagy on in response to metabolic stress³.

TFEB

TFEB drives the transcriptional arm. Following mTORC1 inhibition or lysosomal stress, TFEB translocates to the nucleus and induces the CLEAR gene network, expanding the autophagy machinery and lysosomal biogenesis to meet sustained degradative demand⁴.

This layered control allows autophagy to be quantitatively tuned, matched to nutrient, energetic, and stress inputs, rather than simply switched on or off.

Selective autophagy

Although often depicted as bulk cytoplasmic engulfment, most autophagy in vivo is selective. Cargo specificity is conferred by selective autophagy receptors (SARs) such as p62/SQSTM1, NBR1, OPTN, NDP52, and TAX1BP1. These receptors possess ubiquitin-binding domains that recognize ubiquitinated cargo and LC3-interacting region (LIR) motifs that dock onto membrane-anchored ATG8 proteins, physically tethering cargo to the growing phagophore.

Distinct selective pathways handle distinct substrates:

• Aggrephagy clears ubiquitinated protein aggregates that exceed proteasomal capacity.
• Mitophagy removes damaged mitochondria — see our dedicated mitophagy page for the PINK1/Parkin axis and receptor-mediated routes.
• Xenophagy targets intracellular bacteria and viruses, forming a central axis of cell-autonomous immunity.
• ER-phagy, ribophagy, lipophagy, and ferritinophagy degrade the endoplasmic reticulum, ribosomes, lipid droplets, and ferritin respectively, each using dedicated receptors that couple organelle stress signals to the core ATG machinery⁵.

The selectivity model also extends to non-canonical roles of the conjugation machinery, including conjugation of ATG8 to single membranes (CASM) during phagocytosis and endolysosomal damage, where ATG16L1 is recruited by V-ATPase rather than by WIPI2. These findings expand the functional repertoire of the "autophagy" proteins well beyond classical double-membrane vesicle formation⁵.

Autophagy in disease

Because autophagy sits at the intersection of proteostasis, organelle quality control, and metabolism, its dysregulation contributes to a wide range of pathologies. The direction of dysfunction, insufficient versus excessive, or selective versus global, determines the disease phenotype.

Autophagy in neurodegeneration

Neurons are exceptionally dependent on autophagy because they are post-mitotic, cannot dilute damaged components through division, and rely on long-range trafficking of autophagosomes from distal axons to somatic lysosomes. Basal autophagy is therefore essential for maintaining neuronal proteostasis, and its genetic ablation is sufficient to trigger neurodegeneration in the absence of any disease-associated aggregate-prone protein⁶.

In Alzheimer's, Parkinson's, Huntington's, and ALS/frontotemporal dementia, aggregate-prone proteins (amyloid-β, tau, α-synuclein, mutant huntingtin, TDP-43) accumulate when autophagic clearance is overwhelmed or specifically impaired. Several mechanisms drive this impairment: defective autophagosome biogenesis, disrupted axonal transport of autophagosomes, lysosomal acidification defects, and failure of selective receptors such as p62 and OPTN. Mutations in autophagy and endolysosomal genes (for example, SQSTM1, OPTN, TBK1, GRN, and multiple lysosomal storage disease genes) directly cause or predispose to neurodegeneration, reinforcing the causal link⁶,⁷.

Impaired mitophagy is a particularly prominent contributor in Parkinson's disease, where PINK1 and Parkin loss-of-function disable damaged mitochondria clearance — see the mitophagy page for the mechanistic detail. Restoring autophagic and lysosomal function is now an active therapeutic strategy, with approaches ranging from mTOR-independent autophagy inducers to TFEB activators and lysosomal enhancers.

Autophagy in cancer

Autophagy plays a context-dependent, dual role in cancer. In normal and premalignant tissue, autophagy suppresses tumorigenesis by limiting oxidative damage, removing dysfunctional mitochondria, restraining chronic inflammation, and preserving genomic stability. Loss-of-function of core components such as BECN1, ATG5, and ATG7 promotes tumor initiation in preclinical models, and several autophagy regulators are themselves tumor suppressors or are regulated by tumor suppressors, including TP53 and PTEN⁸.

Once tumors are established, however, many rewire autophagy into a pro-survival dependency. This is most pronounced in RAS- and BRAF-driven cancers, which display "autophagy addiction": elevated basal flux sustains mitochondrial function, nucleotide pools, and redox balance under the metabolic stress of rapid proliferation, hypoxia, and nutrient limitation within the tumor microenvironment. Autophagy also supports resistance to chemotherapy, targeted therapy, and radiotherapy by buffering treatment-induced stress, and it modulates anti-tumor immunity by influencing antigen presentation and the release of damage-associated molecular patterns⁸^,⁹.

This duality has direct therapeutic implications. Autophagy induction may be beneficial in chemoprevention, whereas autophagy inhibition, currently explored through lysosomal blockade and selective ULK1 or VPS34 inhibitors, is being investigated in established tumors, particularly in combination with agents that amplify metabolic or proteotoxic stress.

Autophagy in other diseases

• Cardiovascular disease: Basal autophagy and mitophagy maintain cardiomyocyte function; insufficient flux contributes to cardiac hypertrophy, ischemia–reperfusion injury, and heart failure, whereas excessive or dysregulated autophagy can also drive maladaptive remodeling¹⁰.
• Metabolic disease: Hepatic autophagy and lipophagy regulate lipid mobilization and insulin sensitivity, and their decline with age and obesity contributes to non-alcoholic fatty liver disease and type 2 diabetes.
• Infection and inflammation: Xenophagy captures intracellular bacteria and viruses, while autophagy machinery also regulates inflammasome activity, cytokine secretion, and MHC class II antigen presentation, placing it at the core of innate and adaptive immunity¹¹.

How is autophagy regulated by nutrient and energy status?

Autophagy is reciprocally controlled by mTORC1 and AMPK. Nutrients and growth factors activate mTORC1, which phosphorylates and inhibits ULK1 and sequesters TFEB in the cytosol, suppressing both acute initiation and transcriptional expansion of the pathway. Energy stress activates AMPK, which directly activates ULK1, inhibits mTORC1, and promotes Beclin 1 activity, coordinately switching autophagy on³.

What is selective autophagy and why does it matter?

Selective autophagy is the targeted degradation of specific cargo — damaged organelles, protein aggregates, or pathogens — through cargo receptors that bridge ubiquitinated substrates to ATG8 proteins on the phagophore. It matters because most autophagy in vivo is selective rather than bulk, and because failure of specific selective pathways (for example, mitophagy or aggrephagy) underlies distinct diseases despite overall autophagic capacity appearing intact⁵.

How is autophagic flux measured?

Autophagic flux refers to the rate of cargo delivery to and degradation within lysosomes, not the steady-state abundance of autophagosomes. Because LC3-II can accumulate either from increased biogenesis or from blocked degradation, flux is assessed by comparing LC3-II and p62 levels in the presence and absence of lysosomal inhibitors, or by using tandem fluorescent LC3 reporters that distinguish autophagosomes from autolysosomes¹².

FAQs

References

1. Mizushima, N. & Levine, B. Autophagy in human diseases. N. Engl. J. Med. 383, 1564–1576 (2020).
2. Dikic, I. & Elazar, Z. Mechanism and medical implications of mammalian autophagy. Nat. Rev. Mol. Cell Biol. 19, 349–364 (2018).
3. Kim, J. & Guan, K.L. mTOR as a central hub of nutrient signalling and cell growth. Nat. Cell Biol. 21, 63–71 (2019).
4. Napolitano, G. & Ballabio, A. TFEB at a glance. J. Cell Sci. 129, 2475–2481 (2016).
5. Vargas, J.N.S., Hamasaki, M., Kawabata, T., Youle, R.J. & Yoshimori, T. The mechanisms and roles of selective autophagy in mammals. Nat. Rev. Mol. Cell Biol. 24, 167–185 (2023).
6. Menzies, F.M. et al. Autophagy and neurodegeneration: pathogenic mechanisms and therapeutic opportunities. Neuron 93, 1015–1034 (2017).
7. Fleming, A. et al. The different autophagy degradation pathways and neurodegeneration. Neuron 110, 935–966 (2022).
8. Debnath, J., Gammoh, N. & Ryan, K.M. Autophagy and autophagy-related pathways in cancer. Nat. Rev. Mol. Cell Biol. 24, 560–575 (2023).
9. Amaravadi, R.K., Kimmelman, A.C. & Debnath, J. Targeting autophagy in cancer: recent advances and future directions. Cancer Discov. 9, 1167–1181 (2019).
10. Sciarretta, S., Maejima, Y., Zablocki, D. & Sadoshima, J. The role of autophagy in the heart. Annu. Rev. Physiol. 80, 1–26 (2018).
11. Deretic, V. Autophagy in inflammation, infection, and immunometabolism. Immunity 54, 437–453 (2021).
12. Klionsky, D.J. et al. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition). Autophagy 17, 1–382 (2021).